Wellington Partners

Wellington Partners

  • Home
  • Team
  • Approach
  • Portfolio
  • News
  • Contact

News

Clinical Data with ImCheck’s ICT01 to be Presented at AACR: Positive Results Observed on Safety, Activation of Gamma 9 Delta 2 T Cells and Anti-tumor Immune Response

Details
Published: 09 April 2021
  • portfolio-news

ICT01 activates γ9δ2 T cells that rapidly migrate out of the circulation and secrete IFNγ and TNFα leading to an expanded immune system activation. 

UroMems Completes €23 Million Series B Financing

Details
Published: 06 April 2021
  • portfolio-news

UroMems, announced that it has raised an additional €7 million in a second tranche of its previously announced Series B financing round completed in May 2020.

Immatics Presents Data Update on Dose Escalation from Ongoing ACTengine® Cell Therapy Programs

Details
Published: 18 March 2021
  • portfolio-news

Immatics announced a clinical data update from the dose escalation cohorts of the company’s ongoing Phase 1 trials for its engineered Adoptive Cell Therapy approach (also known as TCR-T). 

  1. Partner Therapeutics Announces Partnership with SIRS Therapeutics and F4 Pharma to Explore Potential Uses for FX06 in Biodefense Applications
  2. eGenesis Announces $125 Million Series C Financing
  3. Creative Balloons closes €15 million growth financing and appoints Frank Gehres as CEO
  4. ONWARD Announces Publication in Nature Demonstrating Blood Pressure Stabilization in People with Spinal Cord Injury

Page 1 of 36

  • Start
  • Prev
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
  • Next
  • End
© Wellington Partners, 2021.
  • WP Technology Funds
  • Contact
  • Imprint
  • Privacy
  • SFDR Disclosures